While the drugs certainly contribute to weight loss and health gains, they also cause a decline in muscle that some doctors ...

For the 2025 outlook, Novo Nordisk now expects 13-21% revenue increase at constant exchange rates (CER). Operating profit is expected at 16-24% growth. However, this forecast, 3% lower for revenue and ...

People taking Eli Lilly's obesity drug, Zepbound, lost nearly 50% more weight than those using rival Novo Nordisk's Wegovy in the first head-to-head study of the blockbuster medications. Clinical ...

They are the two drugs of the moment, the weight loss products promising a miraculous solution to obesity and—in data ...

A pronouncement from President Trump about the category drove their share prices down, although not to bargain-basement ...

People prescribed GLP-1 agents liraglutide (Saxenda) or semaglutide for weight loss decreased their alcohol intake by almost ...

Recent health briefs reveal significant developments in the pharmaceutical sector. Key highlights include Trump's order ...

President Donald Trump's executive order directs pharmaceutical companies to lower their prices to levels closer to those ...

Tirzepatide conferred significantly greater weight loss than semaglutide at 72 weeks for adults with overweight or obesity, ...

Reducing exposure to medicines is always a good thing if similar clinical outcomes can be achieved, and the study suggests it ...

GlobalData analysis predicts the global GLP-1RA market will reach $168bn by 2033, with Novo Nordisk and Eli Lilly to dominate ...

Even if the order takes effect, it will do nothing to address the root causes of the problem it purports to solve.